167 related articles for article (PubMed ID: 35961615)
1. Successful treatment of atopic dermatitis with dupilumab in the setting of X-linked agammaglobulinemia.
Fan YH; Lin TL; Sun HL; Pan HH; Ku MS; Lue KH
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):3032-3034.e1. PubMed ID: 35961615
[No Abstract] [Full Text] [Related]
2. Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia.
Fujishima C; Munemoto S; Hioki C; Sasaki H; Yoshida H; Yamamoto T; Kudo H
Eur J Dermatol; 2022 May; 32(3):416-417. PubMed ID: 36065552
[No Abstract] [Full Text] [Related]
3. Successful dose reduction of dupilumab in atopic dermatitis.
Ardern-Jones MR; Buchanan EE; Njungu S; O'Driscoll D
Br J Dermatol; 2023 Apr; 188(5):678-679. PubMed ID: 36662536
[No Abstract] [Full Text] [Related]
4. Efficacy of Dupilumab for Severe Atopic Dermatitis Co-occurring With Asthma in a Real-World Setting.
Pose K; Laorden D; Hernández N; Villamañán E; Quirce S; Domínguez-Ortega J
J Investig Allergol Clin Immunol; 2023 Jun; 33(3):217-219. PubMed ID: 37318773
[No Abstract] [Full Text] [Related]
5. Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment.
Gori N; Ippoliti E; Antonelli F; Peris K; Chiricozzi A
Clin Exp Dermatol; 2023 Apr; 48(5):558-559. PubMed ID: 36724039
[No Abstract] [Full Text] [Related]
6. Dupilumab use in atopic dermatitis and beyond in skin diseases.
Fourzali K; Golpanian RS; Yosipovitch G
Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
[TBL] [Abstract][Full Text] [Related]
7. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.
Akuffo-Addo E; Nicholas MN; Lansang P
J Cutan Med Surg; 2023; 27(2):177-178. PubMed ID: 36721993
[No Abstract] [Full Text] [Related]
8. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
[No Abstract] [Full Text] [Related]
9.
Doolan BJ; Yeon J; Baker DA; Whitfeld MJ
AIDS Res Hum Retroviruses; 2022 Feb; 38(2):76-79. PubMed ID: 34384267
[No Abstract] [Full Text] [Related]
10. Erythrodermic atopic dermatitis resistant to dupilumab and baricitinib successfully treated with upadacitinib.
Valente C; Duarte B
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e493-e495. PubMed ID: 36306182
[No Abstract] [Full Text] [Related]
11. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
[No Abstract] [Full Text] [Related]
12. Dupilumab nonresponders in atopic dermatitis.
Leung DYM; Ong PY
Ann Allergy Asthma Immunol; 2022 Sep; 129(3):267-268. PubMed ID: 35988971
[No Abstract] [Full Text] [Related]
13. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
Br J Dermatol; 2023 Jul; 189(2):e39. PubMed ID: 37459131
[No Abstract] [Full Text] [Related]
14. Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
Tierney E; Evans P; Broderick V; Wynn R; Irvine AD
Br J Dermatol; 2024 Mar; 190(4):581-583. PubMed ID: 38123149
[No Abstract] [Full Text] [Related]
15. No association between dupilumab use and short-term cancer development in atopic dermatitis patients.
Owji S; Ungar B; Dubin DP; Poplausky D; Young JN; Ghalili S; Han J; Srinivasan D; Packer S; Pavel AB; Correa da Rosa J; Guttman-Yassky E; Gulati N
J Allergy Clin Immunol Pract; 2023 May; 11(5):1548-1551. PubMed ID: 36581076
[No Abstract] [Full Text] [Related]
16. Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab.
Dekkers C; der Wal MMV; El Amrani M; Luin MV; Bakker DS; Bruin-Weller M; van Wijk F
J Invest Dermatol; 2023 Sep; 143(9):1822-1825.e3. PubMed ID: 36997108
[No Abstract] [Full Text] [Related]
17. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.
Sánchez-García V; Navarro-Triviño FJ; Silvestre JF
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1426-e1429. PubMed ID: 37458506
[No Abstract] [Full Text] [Related]
18. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment.
Ferrucci S; Benzecry V; Berti E; Asero R
Clin Exp Dermatol; 2020 Apr; 45(3):345-346. PubMed ID: 31437869
[No Abstract] [Full Text] [Related]
19. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients.
Escolà H; Figueras-Nart I; Bonfill-Orti M; Coll Puigserver N; Martin-Santiago A; Rodríguez Serna M; Sánchez Hernández MC; Sanz-Cabanillas JL; Taberner R; Zaragoza-Ninet V; Pujol RM; Curto-Barredo L
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):e1156-e1160. PubMed ID: 37143399
[No Abstract] [Full Text] [Related]
20. Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis.
Cunningham KN; Alsukait S; Cohen SR; Learned C; Gao DX; Kachuk C; Dumont N; Zipeto A; Rosmarin D
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e765-e767. PubMed ID: 36688247
[No Abstract] [Full Text] [Related]
[Next] [New Search]